Effect of Intragastric Botulinum Type A Injection Combined with a Low-Calorie High-Protein Diet in Adults with Overweight or Obesity

Po-Ke Hsu; Chia-Lin Wu; Yu-Hsuan Yang; James Cheng-Chung Wei

doi:10.3390/jcm11123325

Effect of Intragastric Botulinum Type A Injection Combined with a Low-Calorie High-Protein Diet in Adults with Overweight or Obesity

J Clin Med. 2022 Jun 10;11(12):3325. doi: 10.3390/jcm11123325.

Authors

Po-Ke Hsu^{1

2

3}, Chia-Lin Wu⁴, Yu-Hsuan Yang², James Cheng-Chung Wei^{1

5

6}

Affiliations

¹ Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
² Department of Weight Control Center, Sun Saint Clinic, Zhubei City 302052, Taiwan.
³ Department of Gastroenterology, Changhua Christian Hospital, Changhua City 500209, Taiwan.
⁴ Department of Nephrology, Changhua Christian Hospital, Changhua City 500209, Taiwan.
⁵ Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
⁶ Graduate Institute of Integrated Medicine, China Medical University, Taichung 40201, Taiwan.

Abstract

(1) Background/aims: Intragastric botulinum toxin A injection (IGBI) combined with diet control is a new and effective weight loss method for grade 2 obese patients. However, the application of IGIB on overweight or obese adults still needs further research to confirm its efficacy. (2) Methods: We retrospectively collected medical data from 1 July 2021 to 1 January 2022 from a total of 71 patients without diabetes who participated in the bariatric clinic with a body mass index (BMI) > 25 kg/m2. Forty-nine participants opted for intragastric botulinum injection (IGBI) using 300 units of botulinum injected into the antrum, body, and fundus, followed with a low-calorie high-protein diet course. Another 22 people participated only in the low-calorie high-protein diet course as a placebo group. This study analyzes the weight loss percentage of the two groups. Adverse events after IGBI are also reported in a safety assessment. (3) Results: In terms of the characteristics of the two groups, the mean BMI was 29.3 kg/m2 in the IGBI group and 28.0 kg/m in the placebo group (p = 0.63 without significant difference). Comparing the percent weight loss from baseline in the two groups after 12 weeks, the IGBI group lost 11.5% of their body weight and the placebo group lost 1.8%. In terms of group analysis, the percentages of participants with a weight reduction of at least 5% for the IGBI and placebo groups were 95% and 4%, respectively. For weight reduction of at least 10%, these values for the IGBI and placebo groups were 63% and 4%, respectively. In terms of adverse events after IGBI for 12 weeks, 12 participants (24.4%) had constipation, which was the main side effect. No serious adverse events were observed during the study period. (4) Conclusion: The combination of a low-calorie high-protein diet and IGBI is an effective and safe procedure in overweight or obese adults for weight reduction, but further larger studies are needed.

Keywords: endoscopy; intragastric botulinum injection type A injection; obesity; obesity therapy; overweight.

Grants and funding

This research received no external funding.